Addendum
Relugolix (prostate cancer) – Addendum to Commission A22-108
Report documents
-
Addendum
Relugolix (prostate cancer) – Addendum to Commission A22-108
Dossier assessment
Indication:
Patients with hormone-sensitive prostate cancer
Result of dossier assessment:
Unchanged after addendum:
- Patients with advanced hormone-sensitive prostate cancer who are candidates for local therapy: added benefit not proven
- Patients with advanced hormone-sensitive prostate cancer who are not candidates for local therapy: added benefit not proven
- Patients with advanced hormone-sensitive prostate cancer and with PSA recurrence or clinical recurrence after primary local therapy: added benefit not proven
- Patients with metastatic hormone-sensitive prostate cancer who are candidates for combination therapy: added benefit not proven
- Patients with metastatic hormone-sensitive prostate cancer who are not candidates for combination therapy: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-04-06 A G-BA decision was published.
Project details
- Project no.
- A23-13
- Commission
- Commission awarded on 20.02.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Relugolix (prostate cancer) – Benefit assessment acc. to § 35a Social Code Book V
Status: Commission completed